Float Short %

5.29

Margin Of Safety %

Put/Call OI Ratio

0.08

EPS Next Q Diff

0.48

EPS Last/This Y

EPS This/Next Y

1.18

Price

Target Price

11.96

Analyst Recom

Performance Q

-67.09

Relative Volume

0.2

Beta

2.24

Ticker: AFMD

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-01-23	AFMD	1.09	0.14	0.00	437
2025-01-24	AFMD	1.08	0.14	0.00	453
2025-01-27	AFMD	1.02	0.14	0.00	453
2025-01-28	AFMD	1.025	0.14	0.00	453
2025-01-29	AFMD	0.97	0.14	0.00	448
2025-01-30	AFMD	0.9747	0.13	0.00	466
2025-01-31	AFMD	1	0.13	0.00	466
2025-02-03	AFMD	0.9799	0.13	0.00	466
2025-02-04	AFMD	1	0.13	0.00	477
2025-02-05	AFMD	1.02	0.13	0.00	482
2025-02-06	AFMD	1.05	0.13	0.00	481
2025-02-07	AFMD	1.045	0.12	0.00	491
2025-02-10	AFMD	1.05	0.12	0.00	521
2025-02-11	AFMD	1.04	0.09	0.00	660
2025-02-12	AFMD	0.9831	0.09	0.00	660
2025-02-13	AFMD	1.04	0.08	0.00	705
2025-02-14	AFMD	1.065	0.08	0.00	705
2025-02-18	AFMD	1.06	0.08	0.00	705
2025-02-19	AFMD	1.055	0.08	0.00	725
2025-02-20	AFMD	1.015	0.08	0.00	725
2025-02-21	AFMD	1.0349	0.08	0.00	730
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-01-23	AFMD	1.11	86.8	-	-3.96
2025-01-24	AFMD	1.09	86.8	-	-3.96
2025-01-27	AFMD	1.01	86.8	-	-3.96
2025-01-28	AFMD	1.03	86.8	-	-3.96
2025-01-29	AFMD	1.00	86.8	-	-3.96
2025-01-30	AFMD	0.98	86.8	-	-3.96
2025-01-31	AFMD	1.00	86.8	-	-3.96
2025-02-03	AFMD	0.98	86.8	-	-3.96
2025-02-04	AFMD	1.00	86.8	-	-3.96
2025-02-05	AFMD	1.02	86.8	-	-3.96
2025-02-06	AFMD	1.04	86.8	-	-3.96
2025-02-07	AFMD	1.04	86.8	-	-3.96
2025-02-10	AFMD	1.04	86.8	-	-3.96
2025-02-11	AFMD	1.04	86.8	-	-3.96
2025-02-12	AFMD	0.99	86.8	-	-3.96
2025-02-13	AFMD	1.04	86.8	-	-3.96
2025-02-14	AFMD	1.06	86.8	-	-3.96
2025-02-18	AFMD	1.07	86.8	-	-3.96
2025-02-19	AFMD	1.06	86.8	-	-3.96
2025-02-20	AFMD	1.01	86.8	-	-3.96
2025-02-21	AFMD	1.00	86.8	-	-3.96
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-01-23	AFMD	0.00	9.47	5.71
2025-01-24	AFMD	0.00	9.47	5.71
2025-01-27	AFMD	0.00	9.39	5.71
2025-01-28	AFMD	0.00	9.39	6.03
2025-01-29	AFMD	0.00	9.39	6.03
2025-01-30	AFMD	0.00	9.39	6.03
2025-01-31	AFMD	0.00	9.39	6.03
2025-02-03	AFMD	0.00	14.16	6.03
2025-02-04	AFMD	0.00	14.16	6.03
2025-02-05	AFMD	0.00	14.16	6.03
2025-02-06	AFMD	0.00	14.16	6.03
2025-02-07	AFMD	0.00	14.16	6.03
2025-02-10	AFMD	0.00	14.16	6.03
2025-02-11	AFMD	0.00	14.16	6.03
2025-02-12	AFMD	0.00	14.16	5.29
2025-02-13	AFMD	0.00	14.16	5.29
2025-02-14	AFMD	0.00	14.16	5.29
2025-02-18	AFMD	0.00	15.02	5.29
2025-02-19	AFMD	0.00	15.02	5.29
2025-02-20	AFMD	0.00	15.02	5.29
2025-02-21	AFMD	0.00	15.02	5.29
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-1.03

Avg. EPS Est. Current Quarter

-0.8

Avg. EPS Est. Next Quarter

-0.55

Insider Transactions

Institutional Transactions

15.02

Beta

2.24

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.2

Max Drawdown 5-Year %

-99.1

Target Price

11.96

P/E

Forward P/E

PEG

P/S

16.67

P/B

0.89

P/Free Cash Flow

EPS

-3.64

Average EPS Est. Cur. Y

-3.96

EPS Next Y. (Est.)

-2.78

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-7992.6

Relative Volume

0.2

Return on Equity vs Sector %

-426.2

Return on Equity vs Industry %

-410.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.09

EBIT Estimation

Affimed N.V.

Sector: Healthcare

Industry: Biotechnology

Employees: 76

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

stock quote shares AFMD – Affimed N.V. Stock Price stock today

news today AFMD – Affimed N.V. stock forecast ,stock prediction 2023 2024 2025

marketwatch AFMD – Affimed N.V. yahoo finance google finance

stock history AFMD – Affimed N.V. invest stock market

stock prices AFMD premarket after hours

ticker AFMD fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: AFMD

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y